Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.80 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1780499 | 0.98 | ADRA1A (0.77) | ADRA1ATAAR1AOC3IDO1MTNR1A | |
| SCHEMBL29491077 | 0.89 | TAAR1 (1.00) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL479514 | 0.89 | TAAR1 (1.00) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| Hydrochloric Acid SCHEMBL25232952 | 0.87 | TAAR1 (0.96) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL1081732 | 0.84 | ADRA1A (0.66) | ADRA1ATAAR1AOC3IDO1MTNR1A | |
| SCHEMBL9889155 | 0.82 | ADRA1A (0.64) | ADRA1ATAAR1AOC3IDO1MTNR1A | |
| SCHEMBL5833761 | 0.82 | ADRA1A (0.64) | ADRA1ATAAR1AOC3IDO1MTNR1A | |
| SCHEMBL12524034 | 0.82 | TAAR1 (0.54) | ADRA1ATAAR1MTNR1B | |
| SCHEMBL42578 | 0.81 | ADRA1A (0.72) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL13939377 | 0.81 | ADRA1A (0.54) | ADRA1ATAAR1AOC3IDO1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| EP-1558238-A4 | BETA-HYDROXYPHENYLALDYLAMINES AND THEIR USE FOR TREATING GLAUCOMA | UNIV VIRGINIA COMMONWEALTH (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060106106-A1 | Beta-hydroxyphenylalkylamines and their use for treating glaucoma | VIRGINIA COMMONWEALTH UNIVERSITY | 2006-05-18 | — | — | US | disclosed |
| EP-1558238-A2 | BETA-HYDROXYPHENYLALDYLAMINES AND THEIR USE FOR TREATING GLAUCOMA | Virginia Commonwealth University (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004028451-A2 | β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2004-04-08 | — | — | WO | disclosed |
| US-3992449-A | 2-(γ-Aminopropyl)hydroquinones and process for producing the same | FUJI PHOTO FILM CO., LTD. (JA) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | ADRA1A 960/4885TAAR1 1077/4885AOC3 3025/4885 |
| US-20060106106-A1 | Beta-hydroxyphenylalkylamines and their use for treating glaucoma | PDE3A, QDPR, PDE2A | ADRA1A 63/4885TAAR1 1532/4885AOC3 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.